 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced initial efficacy and safety data from one of the cohorts in ARC-6, a randomized Phase 1b2 platform study, evaluating the novel combination of etrumadenant dual adenosine A2aA2b receptor antagonist plus zimberelimab anti-PD1 antibody and docetaxel in people with taxane-naïve mCRPC who progressed following trea 